SunTrust Banks set a $90.00 price objective on Davita (NYSE:DVA) in a research note published on Tuesday, The Fly reports. SunTrust Banks also issued estimates for Davita’s Q1 2020 earnings at $1.42 EPS, Q2 2020 earnings at $1.54 EPS, Q3 2020 earnings at $1.51 EPS, Q4 2020 earnings at $1.56 EPS, FY2020 earnings at $6.02 EPS and FY2021 earnings at $6.48 EPS.

DVA has been the subject of a number of other reports. Raymond James cut shares of Davita from an outperform rating to a market perform rating in a research report on Thursday, November 7th. Wolfe Research cut shares of Davita from an outperform rating to a market perform rating and set a $57.00 price objective for the company. in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their price objective on shares of Davita from $65.00 to $75.00 and gave the stock a neutral rating in a research report on Friday, December 20th. ValuEngine upgraded shares of Davita from a strong sell rating to a sell rating in a research report on Wednesday, January 15th. Finally, Goldman Sachs Group upgraded shares of Davita from a neutral rating to a buy rating in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $71.43.

DVA stock traded down $0.26 during trading on Tuesday, reaching $85.98. 863,642 shares of the company were exchanged, compared to its average volume of 1,174,992. The company has a 50-day moving average of $79.12 and a two-hundred day moving average of $66.86. The company has a market capitalization of $11.00 billion, a price-to-earnings ratio of 16.01, a P/E/G ratio of 0.63 and a beta of 1.70. Davita has a twelve month low of $43.40 and a twelve month high of $90.15. The company has a debt-to-equity ratio of 4.26, a current ratio of 1.81 and a quick ratio of 1.77.

Davita (NYSE:DVA) last released its quarterly earnings data on Monday, February 10th. The company reported $1.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.20. The business had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.92 billion. Davita had a net margin of 7.12% and a return on equity of 22.93%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.90 EPS. On average, analysts forecast that Davita will post 5.56 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Financial Engines Advisors L.L.C. boosted its stake in shares of Davita by 0.4% in the 4th quarter. Financial Engines Advisors L.L.C. now owns 30,805 shares of the company’s stock valued at $2,311,000 after purchasing an additional 131 shares during the last quarter. Rafferty Asset Management LLC boosted its stake in Davita by 0.8% during the fourth quarter. Rafferty Asset Management LLC now owns 22,309 shares of the company’s stock worth $1,674,000 after acquiring an additional 173 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in Davita by 1.8% during the third quarter. Commonwealth Equity Services LLC now owns 11,537 shares of the company’s stock worth $658,000 after acquiring an additional 200 shares in the last quarter. Cerity Partners LLC boosted its stake in Davita by 1.4% during the third quarter. Cerity Partners LLC now owns 14,284 shares of the company’s stock worth $815,000 after acquiring an additional 203 shares in the last quarter. Finally, Coastline Trust Co boosted its stake in Davita by 2.2% during the third quarter. Coastline Trust Co now owns 10,210 shares of the company’s stock worth $583,000 after acquiring an additional 220 shares in the last quarter. Hedge funds and other institutional investors own 95.40% of the company’s stock.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Read More: How to invest using market indexes

The Fly

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.